Although optimal HbA1C and normal growth and development can be achieved, the use of SGLT2 inhibitors in children younger than 5 is limited by a higher risk of hypoglycemia, particularly after 6 h of fasting. The gene discussed is SLC5A2; the disease is Hypoglycemia.